stephane pyronnet
Translational control of gene expression in hematological tumors
From the genetic information contained in the DNA, our organism manufactures, according to its needs, the proteins necessary for all the mechanisms of life. But for this, each gene needs an intermediary resulting from the “transcription” of the genome: it is ribonucleic acid, or RNA, which is then translated into protein. Although normally very well controlled, alterations or modifications of the mechanisms regulating the translation of RNA into protein have been identified. They contribute to the cancer process or to the resistance to current treatments. Our group aims to identify new translational alterations in hematological tumors, to understand their impact on normal or cancerous cell function and to explore the possibility that they may provide new therapeutic targets.
Recent publications
Gourvest M, De Clara E, Wu HC, Touriol C, Meggetto F, de Thé H, Pyronnet S, Brousset P and Bousquet M. A novel leukemic route of mutant NPM1 through nuclear import of the overexpressed long noncoding RNA LONA. Leukemia 2021, In Press.
Shin S, Nicolle R, Jean C, Samain R, Ayadi M, Raffenne J, Brunel A, Solorzano J, Neuzillet C, Joffre C, Rocchi S, Iovanna J, Dusetti N, Larsson O, Pyronnet S, Bousquet C, Martineau Y. Translatome-based classification reveals a dual metabolic dependency of a new tumor subtype of pancreatic cancer. bioRxiv. 2021.12.23.424227.
Féral K, Jaud M, Philippe C, Di Bella D, Pyronnet S, Rouault-Pierre K, Mazzolini L, Touriol C. ER Stress and Unfolded Protein Response in Leukemia: Friend, Foe, or Both? Biomolecules. 2021 11(2):199. Review.
Alard A, Strehaïano M, Müller D, Lasfargues C, Cassant-Sourdy S, Jean C, Bousquet C, Martineau Y, Pyronnet S. Phosphorylation of the MNK1 substrate eIF4E is not required for response to acute pancreatitis. Pancreatology. 2021 21:677-681.
Müller D, Shin S, Goullet de Rugy T, Samain R, Baer R, Strehaiano M, Masvidal-Sanz L, Guillermet-Guibert J, Jean C, Tsukumo Y, Sonenberg N, Marion F, Guilbaud N, Hoffmann JS, Larsson O, Bousquet C, Pyronnet S*, Martineau Y*. eIF4A inhibition circumvents uncontrolled DNA replication mediated by 4E-BP1 loss in pancreatic cancer. JCI Insight. 2019 4:e121951.
*co-corresponding authors
Alard A, Marboeuf C, Fabre B, Jean C, Martineau Y, Lopez F, Vende P, Poncet D, Schneider RJ, Bousquet C, Pyronnet S. Differential Regulation of the Three Eukaryotic mRNA Translation Initiation Factor (eIF) 4Gs by the Proteasome. Front Genet. 2019 10:254.
Jaud M, Philippe C, Van Den Berghe L, Ségura C, Mazzolini L, Pyronnet S, Laurell H, Touriol C. The PERK Branch of the Unfolded Protein Response Promotes DLL4 Expression by Activating an Alternative Translation Mechanism. Cancers (Basel). 2019 11(2):142.
Elia A, Henry-Grant R, Adiseshiah C, Marboeuf C, Buckley RJ, Clemens MJ, Mudan S, Pyronnet S. Implication of 4E-BP1 protein dephosphorylation and accumulation in pancreatic cancer cell death induced by combined gemcitabin
e and TRAIL. Cell Death Dis. 2017 8(12):3204.
Philippe C, Dubrac A, Quelen C, Desquesnes A, Van Den Berghe L, Ségura C, Filleron T, Pyronnet S, Prats H, Brousset P, Touriol C. PERK mediates the IRES-dependent translational activation of mRNAs encoding angiogenic growth factors after ischemic stress. Sci Signal. 2016 9(426):ra44.
Vaysse C, Philippe C, Martineau Y, Quelen C, Hieblot C, Renaud C, Nicaise Y, Desquesnes A, Pannese M, Filleron T, Escourrou G, Lawson M, Rintoul RC, Delisle MB, Pyronnet S, Brousset P, Prats H, Touriol C. Key contribution of eIF4H-mediated translational control in tumor promotion. Oncotarget. 2015 6(37):39924-40.
Duluc C, Moatassim-Billah S, Chalabi-Dchar M, Perraud A, Samain R, Breibach F, Gayral M, Cordelier P, Delisle MB, Bousquet-Dubouch MP, Tomasini R, Schmid H, Mathonnet M, Pyronnet S, Martineau Y, Bousquet C. Pharmacological targeting of the protein synthesis mTOR/4E-BP1 pathway in cancer-associated fibroblasts abrogates pancreatic tumour chemoresistance. EMBO Mol Med. 2015 7(6):735-53.
Partners
INCa, ANR, Ligue contre le Cancer, Fondation de France, ARC, Région Occitanie, LabEx TOUCAN, EVOTEC, Laboratoires Pierre Fabre.
